Medical Device News Magazine

ImStem Biotechnology

AgeX Therapeutics Licensee ImStem Biotechnology Announces FDA Lifted the Hold and Cleared the Investigational New Drug Application for IMS001 for the Treatment of Multiple...

IMS001 was derived from the pluripotential cell line designated ESI-053 licensed from AgeX Therapeutics.
- Advertisement -spot_img

Latest News

Oblemic: A Comprehensive Review & Latest Research

Oblemic Reviews suggest that by integrating this supplement with healthy lifestyle choices, individuals may see significant improvements in their health. Unlike injectable treatments such as Ozempic and Wegovy, Oblemic is designed to provide similar benefits without the associated side effects.
- Advertisement -spot_img